Dr Thomas Kanyok

Tom Kanyok joined the Bill & Melinda Gates Foundation in February 2007 as a Senior Programme Officer in Field Studies with the Infectious Diseases Department of the Global Health Programme. Tom has a variety of responsibilities in anti-malarial drug resistance and late stage drug development including Malaria, Human African Trypanosomiasis, Visceral Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, and Onchocerciasis.

Tom Kanyok received his B.S. Pharmacy (1989) and his Doctor of Pharmacy (Pharm.D). (1990) at the University of Kentucky, College of Pharmacy and completed a research fellowship in infectious diseases (1990-1993) at the University of Illinois at Chicago, College of Pharmacy where he specialized in anti-mycobacterial drug discovery and development.  His interests in anti-mycobacterial chemotherapy led him to take a faculty position first at the University of Rhode Island, College of Pharmacy (1993-1994), and subsequently at the University of Illinois, College of Pharmacy (1994-1997). 

His involvement with the development of a compound with activity against both tuberculosis and visceral leishmaniasis led to a position at the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (WHO TDR) in Geneva, Switzerland (1997-2007). While at WHO TDR, he was responsible for the development of a number of compounds with activity against malaria, tuberculosis, and visceral leishmaniasis, two of which are registered one which is in regulatory filing and one which completing Phase III of development. He was also responsible for developing WHO TDR’s phase IV strategy for the public health marketing of anti-malarial drugs.

Tom is the Foundation's Project Officer for the NTD work of the Diagnostics Modelling Consortium and he also supports the Consortium's malaria work.

Research area(s):